Damage to the spinal cord rarely heals because the injured nerve cells fail to regenerate. The regrowth of their long nerve fibers is hindered by scar tissue and molecular processes inside the nerves.
The microtubule-stabilizing drug epothilone B (epoB) has shown potential value in the treatment of spinal cord injury (SCI) through diverse mechanisms. However, it remains elusive why a limited ...
The epothilone B analogs are non-taxane tubulin stabilizing compounds that are active in taxane-resistant and -sensitive preclinical models. BMS-247550 is a semi-synthetic epothilone B analog that has ...
Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, As First-Line Therapy in Patients With Metastatic Breast Cancer Previously Treated With Anthracycline Chemotherapy Patients ...
A compound that previously progressed to Phase II clinical trials for cancer treatment slows neurological damage and improves brain function in an animal model of Alzheimer's disease, according to a ...
Co presented updated data from a Phase 1 clinical trial showing that KOS-1584/R1645, an epothilone under co-development with Roche, demonstrated antitumor activity and tolerability in patients with ...
"Kosan's epothilone strategy is to advance KOS-1584 to its next inflection point while seeking a corporate partner to conduct a registration program and advance our preclinical product candidate, ...
Company will evaluate 11 preclinical candidates with nab technology. Abraxis BioScience and The Scripps Research Institute (TSRI) are collaborating to develop and commercialize an epothilone ...
Roche and Kosan Biosciences Incorporated they have signed a collaboration agreement to globally co-develop and co-commercialize Kosan''s new generation anti-cancer drug candidate, KOS-862 (Epothilone ...
CHESTNUT HILL, MA (11/2/11) – Research carried out at Boston College, in collaboration with scientists at MIT and the University of Oxford, has led to the development of an efficient and highly ...
HAYWARD, Calif., April 14 -- Kosan Biosciences Incorporated NASDAQ: KOSN today announced that the Phase 2 trial of epothilone KOS-1584 in patients with non-small cell lung cancer has been initiated.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results